Fibrocor Therapeutics

Fibrocor Therapeutics strengthens its clinical strategy with the appointment of four world-leading nephrology and genetics experts to its Clinical Advisory Board (CAB), reinforcing its scientific leadership in Alport Syndrome. The new CAB brings unparalle

Fibrocor Therapeutics Inc. (

Fibrocor Therapeutics strengthens its clinical strategy with the appointment of four world-leading nephrology and genetics experts to its Clinical Advisory Board (CAB), reinforcing its scientific

This BIC Presents podcast is a discussion with William Newsome from Fibrocor Therapeutics, a BIC Stage 2 Accelerator company. A Monument Mountain and Berkshire Community College alumni, Newsome discusses the path which lead him into a career in Biotech, F

with Dr. Dennis Rebelo This episode reflects on Bill's journey, starting with his move to the Berkshires, where his love for nature, outdoor recreation, and gardening took root. He shares his humble beginnings, shaped by his creative mother, and how inter

In another significant mAb collaboration. Fibrocor Therapeutics agreed a research and development (R&D) collaboration with the McQuade Center for Strategic Research and Development (MSRD) in March 2024 to advance its Alpon Syndrome programme. Phase I clin

Tune in to "Advancements with Ted Danson" to discover how Fibrocor Therapeutics is leading the charge in reshaping the future of fibrosis treatment. Join William Newsome, President and CEO, Dr. Richard Gilbert, Chief Scientific Officer, Piet Wigerinck, Ch

Agreement includes a single digit million US$ upfront payment and additional funding that has the potential to cover the cost of studies through Phase 1b Deal is a major step forward for Fibrocor's plans to develop FIB918, its monoclonal antibody for Alpo

/PRNewswire/ -- Fibrocor Therapeutics Inc. (